MY148409A - Anti-mag antibodies - Google Patents

Anti-mag antibodies

Info

Publication number
MY148409A
MY148409A MYPI20032945A MYPI20032945A MY148409A MY 148409 A MY148409 A MY 148409A MY PI20032945 A MYPI20032945 A MY PI20032945A MY PI20032945 A MYPI20032945 A MY PI20032945A MY 148409 A MY148409 A MY 148409A
Authority
MY
Malaysia
Prior art keywords
seq
set out
antibodies
chain variable
variable domain
Prior art date
Application number
MYPI20032945A
Other languages
English (en)
Inventor
Jonathan Henry Ellis
Volker Germaschewski
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0218230A external-priority patent/GB0218230D0/en
Priority claimed from GB0218229A external-priority patent/GB0218229D0/en
Priority claimed from GB0218232A external-priority patent/GB0218232D0/en
Priority claimed from GB0218234A external-priority patent/GB0218234D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MY148409A publication Critical patent/MY148409A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI20032945A 2002-08-06 2003-08-05 Anti-mag antibodies MY148409A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0218230A GB0218230D0 (en) 2002-08-06 2002-08-06 Antibodies
GB0218229A GB0218229D0 (en) 2002-08-06 2002-08-06 Antibodies
GB0218232A GB0218232D0 (en) 2002-08-06 2002-08-06 Antibodies
GB0218234A GB0218234D0 (en) 2002-08-06 2002-08-06 Antibodies

Publications (1)

Publication Number Publication Date
MY148409A true MY148409A (en) 2013-04-30

Family

ID=31721633

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20032945A MY148409A (en) 2002-08-06 2003-08-05 Anti-mag antibodies

Country Status (23)

Country Link
US (2) US7612183B2 (enExample)
EP (1) EP1526868B1 (enExample)
JP (1) JP4528121B2 (enExample)
KR (1) KR101078459B1 (enExample)
CN (1) CN100542607C (enExample)
AR (1) AR040778A1 (enExample)
AU (1) AU2003255390B2 (enExample)
BR (1) BR0312456A (enExample)
CA (1) CA2494008C (enExample)
CY (1) CY1114919T1 (enExample)
DK (1) DK1526868T3 (enExample)
ES (1) ES2440652T3 (enExample)
IL (1) IL165478A (enExample)
IS (1) IS7576A (enExample)
MX (1) MXPA05001468A (enExample)
MY (1) MY148409A (enExample)
NO (1) NO333876B1 (enExample)
NZ (1) NZ537123A (enExample)
PL (1) PL211014B1 (enExample)
PT (1) PT1526868E (enExample)
SI (1) SI1526868T1 (enExample)
TW (1) TWI323265B (enExample)
WO (1) WO2004014953A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7981420B2 (en) 2000-12-22 2011-07-19 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. Therapeutic use of antibodies directed against repulsive guidance molecule (RGM)
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
AR040778A1 (es) * 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
GB0306309D0 (en) * 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
EP2418278A3 (en) * 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
WO2007039256A2 (de) 2005-09-30 2007-04-12 Abbott Gmbh & Co. Kg Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
SI2500030T2 (sl) 2005-11-04 2018-11-30 Genentech, Inc. Uporaba inhibitorjev komplementarnih procesov za zdravljenje očesnih bolezni
EP2021373A4 (en) * 2006-05-31 2010-06-02 Hanwa Chemical Corp MONOCLONAL ANTIBODY VCAM-1 SPECIFIC
RS58233B1 (sr) 2006-11-02 2019-03-29 Genentech Inc Humanizovana anti-faktor d antitela i njihove upotrebe
WO2009051957A2 (en) * 2007-10-16 2009-04-23 Nuvelo, Inc. Antibodies to irem-1
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
UY31809A (es) 2008-05-06 2009-12-14 Glaxo Group Ltd Encapsulación de agentes biológicamente activos
TW201029662A (en) 2008-12-19 2010-08-16 Glaxo Group Ltd Novel antigen binding proteins
SG172855A1 (en) * 2009-01-29 2011-08-29 Abbott Lab Il-1 binding proteins
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
BR112012013734A2 (pt) 2009-12-08 2017-01-10 Abbott Gmbh & Co Kg anticorpos monoclonais contra a proteína rgm a para uso no tratamento da degeneração da camada de fibras nervosas da retina.
US8663950B2 (en) 2010-01-11 2014-03-04 Arizona Board Of Regents Production of a monoclonal antibody therapeutic against west nile virus in plants
TW201210612A (en) 2010-06-03 2012-03-16 Glaxo Group Ltd Humanised antigen binding proteins
EP2579895A4 (en) 2010-06-14 2013-12-18 Vaccinex Inc ANTI-VEGF ANTIBODIES AND USES THEREOF
US8974782B2 (en) * 2011-02-07 2015-03-10 Glaxo Group Limited Treatment of stroke comprising anti-MAG antibodies
SG11201404263TA (en) 2012-01-27 2014-08-28 Abbvie Deutschland Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
US9308196B2 (en) * 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US10093978B2 (en) 2013-08-12 2018-10-09 Genentech, Inc. Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms
WO2015091144A1 (en) 2013-12-20 2015-06-25 F. Hoffmann-La Roche Ag Improved recombinant polypeptide production methods
CA2940579A1 (en) 2014-03-13 2015-09-17 Universitaet Basel Carbohydrate ligands that bind to igm antibodies against myelin-associated glycoprotein
MX2016014160A (es) 2014-05-01 2017-02-16 Genentech Inc Variantes del anticuerpo anti-factor d y sus usos.
IL302486A (en) 2015-06-24 2023-06-01 Hoffmann La Roche Antibodies against the transnephrine receptor with adapted affinity
AU2016323377B2 (en) 2015-09-16 2021-04-15 Universität Basel Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids
KR20180054824A (ko) * 2015-09-29 2018-05-24 셀진 코포레이션 Pd-1 결합 단백질 및 이의 사용 방법
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CN114057885A (zh) 2015-10-02 2022-02-18 豪夫迈·罗氏有限公司 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法
CN108472382A (zh) 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 抗-因子d抗体变体缀合物及其用途
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
US10766958B2 (en) 2016-09-19 2020-09-08 Celgene Corporation Methods of treating vitiligo using PD-1 binding antibodies
BR112019004733A2 (pt) 2016-09-19 2019-05-28 Celgene Corp métodos de tratamento de distúrbios imunes usando proteínas de ligação a pd-1
CN109481673A (zh) * 2017-09-12 2019-03-19 中国科学院苏州纳米技术与纳米仿生研究所 促进脑损伤神经修复的组合物及其应用与评价方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DK84787D0 (da) 1987-02-19 1987-02-19 Axel Olsen Listesystem til foering af elektriske stroemforsynings- og/eller svagstroemsledere
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
US5154927A (en) * 1989-01-19 1992-10-13 Wm. Wrigley Jr. Company Gum composition containing dispersed porous beads containing active chewing gum ingredients and method
US5182107A (en) 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5527527A (en) 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5154924A (en) 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
FI93513C (fi) 1993-11-04 1995-04-25 Matti Kangasvuori Ketju sekä menetelmä ketjun tekemiseksi
AU703152B2 (en) * 1994-01-25 1999-03-18 Biogen Ma Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
GB9403250D0 (en) * 1994-02-21 1994-04-13 Univ Mcgill Therapeutic use of myelin-associated glycoprotein (mag)
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
US6576607B1 (en) * 1995-04-19 2003-06-10 Acorda Therapeutics Methods using CNS neurite outgrowth modulators
US5792743A (en) * 1995-04-19 1998-08-11 Acorda Therapeutics Method for promoting neural growth comprising administering a soluble neural cell adhesion molecule
KR19990007893A (ko) 1995-04-19 1999-01-25 론 코헨 중추신경계（ｃｎｓ） 축삭 성장 모듈레이터, 이를 구현 및 사용하는 조성물, 세포 및 방법
CA2225691A1 (en) * 1995-06-27 1997-01-16 Research Foundation Of Cuny, Hunter College Compositions and methods using myelin-associated glycoprotein (mag) and inhibitors thereof
CN1196733A (zh) * 1995-06-30 1998-10-21 持田制药株式会社 抗Fas配体抗体和利用抗Fas配体抗体的测定方法
US5962434A (en) 1995-08-25 1999-10-05 The Johns Hopkins University School Of Medicine Compounds for stimulating nerve growth
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114506A (en) * 1996-09-20 2000-09-05 General Hospital Corporation Composition and method for enhancing fibrinolysis
AU748143B2 (en) * 1997-10-28 2002-05-30 University Of British Columbia, The Immunological compositions and methods of use to transiently alter mammalian central nervous system myelin to promote neuronal regeneration
EP1032420A4 (en) * 1997-11-14 2004-09-15 Euro Celtique Sa IMMUNOGLOBULIN MOLECULES WITH SYNTHETIC VARIABLE REGION AND MODIFIED SPECIFICITY
WO1999053945A1 (en) 1998-04-16 1999-10-28 Samuel David Neuron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
DK1098972T3 (da) 1998-07-22 2011-01-03 Smithkline Beecham Ltd Protein med lighed med neuroendokrinspecifikt protein samt cDNA kodende derfor
MXPA01002674A (es) * 1998-09-14 2002-06-04 Ostergaard Pedersen Lars Un metodo para producir una proteina de la superfamilia de inmunoglobulina funcional.
ES2529196T3 (es) 1998-11-06 2015-02-17 University Of Zurich Secuencias de nucleótidos y proteínas de genes Nogo y métodos basados en estas
CA2361124A1 (en) 1999-01-22 2000-07-27 Matthew John During Vaccine-mediated treatment of neurological disorders
GB9908533D0 (en) 1999-04-14 1999-06-09 Novartis Ag Organic compounds
US8101553B1 (en) 2000-02-22 2012-01-24 Medical & Biological Laboratories Co., Ltd. Antibody library
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
US20040002790A1 (en) * 2002-06-28 2004-01-01 Paul Senn Sensitive devices and sensitive applications
AR040778A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
GB0306309D0 (en) * 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment

Also Published As

Publication number Publication date
US8071731B2 (en) 2011-12-06
MXPA05001468A (es) 2005-06-06
KR101078459B1 (ko) 2011-10-31
PT1526868E (pt) 2014-01-07
IL165478A (en) 2010-12-30
PL375405A1 (en) 2005-11-28
US20060165681A1 (en) 2006-07-27
TWI323265B (en) 2010-04-11
JP4528121B2 (ja) 2010-08-18
NO333876B1 (no) 2013-10-07
TW200403254A (en) 2004-03-01
PL211014B1 (pl) 2012-03-30
CA2494008C (en) 2012-12-11
US20090053214A1 (en) 2009-02-26
CN1671417A (zh) 2005-09-21
HK1077206A1 (en) 2006-02-10
EP1526868B1 (en) 2013-10-23
AU2003255390A1 (en) 2004-02-25
NZ537123A (en) 2007-05-31
BR0312456A (pt) 2005-04-19
KR20050049470A (ko) 2005-05-25
CN100542607C (zh) 2009-09-23
IS7576A (is) 2004-11-30
DK1526868T3 (da) 2014-01-13
CA2494008A1 (en) 2004-02-19
NO20045323L (no) 2005-02-10
WO2004014953A2 (en) 2004-02-19
US7612183B2 (en) 2009-11-03
CY1114919T1 (el) 2016-12-14
SI1526868T1 (sl) 2014-01-31
AR040778A1 (es) 2005-04-20
ES2440652T3 (es) 2014-01-29
WO2004014953A3 (en) 2004-05-06
EP1526868A2 (en) 2005-05-04
JP2006512899A (ja) 2006-04-20
AU2003255390B2 (en) 2011-02-03

Similar Documents

Publication Publication Date Title
MY148409A (en) Anti-mag antibodies
JP2006512899A5 (enExample)
HRP20090527T1 (hr) Imunoglobulini za neutraliziranje nogo-a, namijenjeni liječenju neuroloških bolesti
GEP20074222B (en) Antibodies to cd40
JP2020500538A5 (enExample)
NZ594275A (en) B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
PE20050205A1 (es) Moleculas de union a cd20
NZ599196A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
FI4045533T3 (fi) Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2)
PE20061324A1 (es) Anticuerpos anti-il-6, composiciones, metodos y usos
WO2005094446A3 (en) Anti-myostatin antibodies
NZ598063A (en) Gram-positive bacteria specific binding compounds
NZ603972A (en) Anti-fgfr2 antibodies
NZ625807A (en) Human anti-b7rp1 neutralizing antibodies
JP2019522961A5 (enExample)
JP2017528476A5 (enExample)
FI3740504T3 (fi) CD70-yhdistelmähoito
TW200720289A (en) Antibodies against CCR5 and uses thereof
RU2588467C3 (ru) Стабильные и растворимые антитела, ингибирующие vegf
PE20070317A1 (es) Agentes de union a esclerostina o fragmentos de esclerostina
NZ596712A (en) Anti cxcr4 antibodies for the treatment of hiv
PL359854A1 (en) Antibodies to human mcp-1
NZ610153A (en) Novel anti-dr5 antibody
RU2016122340A (ru) Il-17a-связующий агент и способы его применения
NZ599779A (en) Compositions and methods for treating inflammatory disorders